Top Ten articles in the pharma industry this week
pharmafile | October 14, 2016 | News story | Medical Communications | news, october, pharmaceutical, top 10, top ten, top ten stories
This week has seen a lot of news regarding specific drugs going through trial and some impressive results within. Read here to catch up on the biggest news stories that have been viewing on our website.
10. Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants
The FDA has enforced a ‘Class III’ recall of Sun’s anti-depressants over dissolution specifications
9. Novartis’ Zykadia more effective than chemo, new study shows
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression of non-small-cell lung cancer (NSCLC).
8. Roche’s lung cancer success spells competition for BMS’ Opdivo
Successful trial results show the drug significantly improved overall survival in non-small-cell lung cancer sufferers compared to chemotherapy treatment docetaxel.
7. AstraZeneca forced to abandon Phase II trial
AstraZeneca, in collaboration with Synairgen, were forced to stop a trial testing a new treatment for severe asthma exacerbations due to insufficient patients being able to make the endpoint.
6. MSD’s Keytruda twice as successful against standard therapy for lung cancer
Keytruda was found to shrink tumours in 55% of patients as opposed to 29% of those treated via chemotherapy alone.
5. Failure for BMS’ Opdivo in lung cancer trial
Blockbuster drug fails to meet its primary endpoint in significantly prolonging progression-free survival versus chemotherapy.
4. Tesaro’s ovarian cancer drug success threatens market rivals
The PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable benefit in treating women with recurrent ovarian cancer with success in 70% of patients.
3. Astrazeneca wins major drug approval by NICE
AstraZeneca’s lung-cancer drug, Tagrisso, will be made available to people with a certain type of lung cancer through the Cancer Drugs Fund.
2. Transgene announce key partnership with Merck KGaA and Pfizer
The three companies have formed a collaboration to trial a drug combination to treat HPV-Positive head and neck cancer.
1. AstraZeneca sells off third drug in five days
AstraZeneca announced that they would divest the right to Rhinocort Aqua to Cilag GmbH for $330 million.
Related Content
FlyPharma Europe, Vienna – 23-24 October 2024 conference
Samedan announces that on 23-24 October 2024, their FlyPharma Conference will make a welcome return …
FDA release statement exercising caution around dosing errors associated with compounded injectable semaglutide products
This week, the US Food and Drug Administration (FDA) and have issued warnings regarding dosing …
Zumutor’s cancer drug trial cleared by FDA
On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …
